Translating Landmark Trial-Based Evidence to the Front Lines of Care for Pancreatic Cancer: The Evolving Trial-Based and Guideline-Supported Role for Nanoliposomal Topoisomerase Inhibitors in Metastatic Pancreatic Adenocarcinoma

Translating Landmark Trial-Based Evidence to the Front Lines of Care for Pancreatic Cancer: The Evolving Trial-Based and Guideline-Supported Role for Nanoliposomal Topoisomerase Inhibitors in Metastatic Pancreatic Adenocarcinoma


Published

April 20, 2018

Created by

CMEducation Resources symposium